We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
151
Praxis Precision Medicines
PRAX
$8.64B
$766K 0.03%
5,000
– –
DTIL icon
152
Precision BioSciences
DTIL
$188M
$692K 0.02%
7,484
– –
UHT
153
Universal Health Realty Income Trust
UHT
$587M
$657K 0.02%
11,258
– –
CHCT
154
Community Healthcare Trust
CHCT
$506M
$629K 0.02%
14,900
– –
NHI icon
155
National Health Investors
NHI
$3.61B
$592K 0.02%
10,038
– –
EWTX icon
156
Edgewise Therapeutics
EWTX
$4.81B
$587K 0.02%
60,550
– –
UHS icon
157
Universal Health Services
UHS
$10.2B
$580K 0.02%
4,000
-56,023
-93% -$7.75M
ARDX icon
158
Ardelyx
ARDX
$1.24B
$577K 0.02%
539,408
– –
TCRX icon
159
TScan Therapeutics
TCRX
$48.1M
$560K 0.02%
200,000
– –
MOR
160
DELISTED
MorphoSys AG American Depositary Shares
MOR
$555K 0.02%
81,867
– –
RNAM
161
DELISTED
Avidity Biosciences
RNAM
$489K 0.02%
+26,452
New +$449K
BCYC
162
Bicycle Therapeutics
BCYC
$275M
$443K 0.02%
+10,086
New +$471K
RPTX
163
DELISTED
Repare Therapeutics
RPTX
$415K 0.01%
29,150
– –
BDTX icon
164
Black Diamond Therapeutics
BDTX
$102M
$366K 0.01%
131,990
– –
ONEM
165
DELISTED
1Life Healthcare
ONEM
$346K 0.01%
31,266
– –
FUSN
166
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$337K 0.01%
43,394
– –
NKTX icon
167
Nkarta
NKTX
$162M
$330K 0.01%
28,988
– –
ZIMV
168
DELISTED
ZimVie
ZIMV
$324K 0.01%
+14,202
New +$335K
SPPI
169
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$148K 0.01%
114,670
– –
YARW
170
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$88K ﹤0.01%
150
– –
CRBP icon
171
Corbus Pharmaceuticals
CRBP
$174M
$82K ﹤0.01%
5,144
– –
ORKA
172
Oruka Therapeutics
ORKA
$5.92B
$75K ﹤0.01%
2,705
– –
ALR
173
DELISTED
AlerisLife Inc
ALR
$52K ﹤0.01%
24,237
– –
BLCM
174
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$13K ﹤0.01%
6,000
– –
NXGL icon
175
NexGel
NXGL
$3.88M
$8K ﹤0.01%
+4,243
New +$9.53K
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.